Abstract
Recent study implicates that gastric cancer stem cells (CSCs) are capable of generating multiple types of cells to promote tumor growth and heterogeneity important for the development of gastric cancer. However, knowledge is limited regarding the expression and characteristics of marker-positive gastric CSCs. Therefore, gastric CSCs from a series of human gastric cancer cell lines (SNU-5, SNU-16, BGC-823, PAMC-82, MKN-45, and NCI-N87) using four putative CSC surface markers (CD44, CD90, CD133, and epithelial-cell adhesion molecule) were investigated the underlying mechanisms regulating such subpopulations. Only SNU-5 and SNU-16 exhibited independent co-expression of CD44+ and CD90+, which exhibited spheroid-colony formation in vitro and tumor formation in immunodeficient mice. Functional studies revealed that CD44+ cells were more invasive compared with CD90+ cells, whereas CD90+ cells exhibited higher levels of proliferation than CD44+ cells. Furthermore, serial xenotransplantation in mice of CD44+/CD90+ cells derived from SNU-5 and SNU-16 revealed rapid growth of CD90+ cells in subcutaneous lesions and a high metastatic capacity of CD44+ cells in the lung. Mechanistic analyses revealed that CD44+ cells underwent epithelial-to-mesenchymal transition (EMT) following acquisition of mesenchymal features, whereas CD90+ cells enhanced the activation of retinoblastoma phosphorylation at Ser780 and oncogenic cell cycle regulators. The expression of CD44 and CD90 in gastric cancer tissues was associated with distant metastasis and the differentiation state of tumors. These results demonstrated that CD44 and CD90 are specific biomarkers capable of identifying and isolating metastatic and tumorigenic CSCs through their ability to regulate EMT and the cell cycle in gastric cancer cell lines.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
Han ME, Oh SO (2013) Gastric stem cells and gastric cancer stem cells: anatomy Cell. Biology 46:8–18
Stojnev S, Krstic M, Risticpetrovic A, Stefanovic V, Hattori T (2014) Gastric cancer stem cells: therapeutic targets. Gastric Cancer 17:13–25
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016) Gastric cancer. Lancet 388:2654–2664
Xu G, Shen J, Ou Yang X, Sasahara M, Su X (2013) Cancer stem cells: the ‘heartbeat’ of gastric cancer. J Gastroenterol 48:781–797
Singh SR (2013) Gastric cancer stem cells: a novel therapeutic target. Cancer Lett 338:110–119
Clevers H (2011) The cancer stem cell: premises, promises, and challenges. Nat Med 17:313–319
Zhu Y, Luo M, Brooks M, Clouthier SG, Wicha MS (2014) Biological and clinical significance of cancer stem cell plasticity. Clin Transl Med 3:32
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC (2009) Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006–1020
Zhang C, Li C, He F, Cai Y, Yang H (2011) Identification of CD44 + CD24 + gastric cancer stem cells. J Cancer Res Clin Oncol 137:1679–1686
Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, Yoon S, Baek SY, Kim BS et al (2011) Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 68:3589–3605
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng D, Xu F, Zhang Y, Li C, Liang Y, Chen Z (2012) Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 31:671–682
Nosrati A, Naghshvar F, Khanari S (2014) Cancer stem cell markers CD44, CD133 in primary gastric adenocarcinoma. Int J Mol Cell Med 3:279–286
Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K (2012) Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumorigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-beta. J Pathol 228:391–404
Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS (2014) CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res 20:3974–3988
Xia P, Song CL, Liu JF, Wang D, Xu XY (2015) Prognostic value of circulating CD133(+) cells in patients with gastric cancer. Cell Prolif 48:311–317
Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890
De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110
Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, Cui YH, Bian XW (2011) Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett 310:46–52
Carrasco E, Alvarez PJ, Prados J, Melguizo C, Rama AR, Aránega A, Rodríguez-Serrano F (2014) Cancer stem cells and their implication in breast cancer. Eur J Clin Invest 44:678–687
Feduska J, Lee C, Ponnazhagan S (2016) Abstract 2539: cell cycle regulation influences the phenotype of breast and prostate cancer stem cells in vitro. Cancer Res 76:2539
Takeishi S (2015) Cell cycle regulation in cancer stem cells. Nihon rinsho Jpn J Clin Med 73:779–783
Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Siner MJ, Reed MW (2000) Quantitative reverse transcription polymerase chain reaction to study mRNA decay: comparison of end point and real-time methods. Anal Biochem 285:194–204
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344
Brooks MD, Burness ML, Wicha MS (2015) Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell 17:260–271
Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H, Costea DE, Mackenzie IC (2011) Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 71:5317–5326
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988
Hong SP, Jing W, Bang S, Park S, Song SY (2010) CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer 125:2323–2331
Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S, Taniguchi H, Akasu T, Fujita S, Nakagama H, Okamoto K (2012) Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 72:5101–5110
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H et al (2013) Discrete nature of EpCAM + and CD90 + cancer stem cells in human hepatocellular carcinoma. Hepatology 57:1484–1497
Weiss TS, Dayoub R (2017) Thy-1 (CD90)-positive hepatic progenitor cells, hepatoctyes, and non-parenchymal liver cells Isolated from human livers. Methods Mol Biol 1506:75–89
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611–629
Raimondi C, Gianni W, Cortesi E, Gazzaniga P (2010) Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr Cancer Drug Targets 10:496–508
Ishiwata T (2016) Cancer stem cells and epithelial-mesenchymal transition: novel therapeutic targets for cancer. Pathol Int 66:601
Mejlvang J, Kriajevska M, Vandewalle C, Chernova T, Sayan AE, Berx G, Mellon JK, Tulchinsky E (2007) Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol Biol Cell 18:4615–4624
Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, Day ML (2006) Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 66:11897–11906
Chen T, Yang K, Yu J, Meng W, Yuan D, Bi F, Liu F, Liu J, Dai B, Chen X, Wang F, Zeng F, Xu H, Hu J, Mo X (2012) Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 22:248–258
Acknowledgements
This study was funded by grants from CAMS Innovation Fund for Medical Sciences (Grant Nos. 2016-I2M-3-013 and 2017-I2M-3-005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All animal experiments were approved by The Animal Care and Use Committee of Cancer Hospital, Chinese Academy of Medical Science, and Peking Union Medical College (Beijing, China).
Informed consent
Patients signed informed consent forms for sample collection.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shu, X., Liu, H., Pan, Y. et al. Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines. Mol Cell Biochem 459, 35–47 (2019). https://doi.org/10.1007/s11010-019-03548-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-019-03548-1